Study of a Potential New Treatment for Patients With Toxic Epidermal Necrolysis (TEN)

Pilot Study Comparing Remicade (Infliximab) vs. Standard Care in the Treatment of Toxic Epidermal Necrolysis

To determine whether treatment of patients who have toxic epidermal necrolysis with a drug called remicaide increases the number of patients who are alive 30 days laters.

This is a pilot (preliminary) study. Patients with a diagnosis of TEN will be asked to consider participating. The study intervention is a single intravenous dose of remicaide (5 mg/kg). Standard supportive care will be given. The percentage of patients alive at 30 days after treatment with remicaide will be compared to historical controls.

Inclusion Criteria:

• Admission to burn unit with a histologic diagnosis of TENs

Exclusion Criteria:

• Pregnancy
• hypersensitivity to remicaide
• history of heart failure
• documented bacteremia
• history of cancer
• inability to consent